<DOC>
	<DOCNO>NCT00425178</DOCNO>
	<brief_summary>FGF-1 use treatment patient diabetic venous stasis ulcer . Procedure include topical administration FGF-1 placebo evaluation safety , pharmacokinetics , wound improvement .</brief_summary>
	<brief_title>FGF-1 Topical Administration Treatment Diabetic Venous Stasis Ulcers</brief_title>
	<detailed_description>Patients meet eligibility criterion randomize receive topical administration either FGF-1 placebo . Patients evaluate day 1 7 , post-treatment safety , pharmacokinetics , wound healing .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Postphlebitic Syndrome</mesh_term>
	<mesh_term>Postthrombotic Syndrome</mesh_term>
	<mesh_term>Varicose Ulcer</mesh_term>
	<criteria>Eligibility Criteria : Informed consent Female patient postmenopausal , sterilize , adequate birth control Fullthickness low extremity diabetic venous statis ulcer specific target size least 8 week 1 year duration Target ulcer freshly debrided screen within two week prior screen Adequate blood supply define transcutaneous oxygen pressure &gt; 20 mmHG ABI great equal 0.4 Compliance nonweight bear regimen diabetic patient Compliance wound care regimen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>Chronic wound</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Ulcers</keyword>
	<keyword>Arterial bypass</keyword>
	<keyword>Angioplasty</keyword>
	<keyword>Diabetic ulcer</keyword>
</DOC>